HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Euro Results Round-Up: Galenica, Recordati And Karo Pharma

Executive Summary

The latest Q2 and first-half financial results from European consumer health players. Featuring Switzerland's Galenica, Italy's Recordati and Sweden's Karo Pharma.

You may also be interested in...

EU Business Round-Up: Galenica Acquires Spagyros, Karo Offloads OTCs, And Ceres Gets New Owners

The latest European business news: Galenica strengthens its porfolio in Switzerland with Spagyros; Sweden's Karo offloads OTCs to Evolan; and Ceres Pharma sold to French private-equity firm.

Galenica Grows In Switzerland With Dr. Wild OTC Portfolio

Galenica has acquired an OTC portfolio from Switzerland's Dr. Wild, led by the market leading vitamin D supplements Vitamin D3 Wild Oil and VI-DE 3, which generated sales of CHF19m in 2020.

EU Business Round-Up: ColdZyme Heading To MENA, Kerry Expands Probiotics Offering, Galenica Launches Vita-Merfen

Latest EU company news: Enymatica strikes deal to take its ColdZyme common cold product into MENA; Ireland's Kerry snaps up Canadian probiotics specialist Bio-K Plus; and Switerland's Galenica relaunches Vita-Merfen after a five-year absence. 

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts